Cannabicitran, or CBT, is a minor cannabinoid found in hemp-based cannabis that is chemically similar to THC but does not produce intoxicating effects. In fact, CBT may help mitigate THC’s intoxicating properties by blocking the chemical transformations that produce a THC high. In this article, we’ll explore CBT in detail, including its properties and applications, and its role in the future of cannabinoid research.
What is Cannabicitran?
Cannabicitran is a minor cannabinoid that was first discovered in 1966, but it wasn’t officially declared a cannabinoid until 2011. It is chemically distinct from another cannabinoid called cannabitriol, which shares the same abbreviation (CBT). Cannabicitran develops from CBDA, while cannabitrol develops from THCA. As such, cannabicitran is more prominent in hemp-type cannabis, whereas cannabitrol is more prominent in marijuana-type cannabis.
CBT Properties and Applications
CBT is a minor cannabinoid, and its therapeutic potential is currently limited due to minimal research on the compound. However, researchers have noted that CBT seems to minimize the effects of THC despite its similar structure. Another early study suggests that CBT may help reduce intraocular pressure (IOP) in rabbits. CBT also developed in the Chinese medicinal plant Rhododendron Anthopogonoides, which was often used to treat respiratory issues. Although current CBT research has not confirmed its application as a bronchodilator, this potential warrants further investigation.
CBT does not crystalize like other cannabinoids, making it an effective thinning agent for vaporizer cartridges. Consequently, manufacturers can use CBT to create pure vapeable cannabinoid-based oils and cartridges.
Cannabicitran and the Future of Cannabinoid Research
Recent legislative efforts have increased access to many cannabis cultivars and made it easier for researchers to fund and study them. This has allowed for the study of minor cannabinoids like cannabicitran to better understand the entourage effect. As we discover and map new cannabinoids and synthetic processes, we gain a better understanding of cannabis, the endocannabinoid system, and how they all work together to promote plant-based wellness.
Soon, we will be able to fine-tune our cannabinoid intake with precisely measured cannabinoid-based products. Dosing and consumption methods will also become more standardized, thus improving legalization efforts and overall access to these amazing compounds.
Final Thoughts About Cannabicitran
Cannabicitran, or CBT, is a non-crystalizing cannabis compound that can lend to the purity of other cannabinoid-based oils. Additionally, it could add therapeutic potential by contributing to the entourage effect, though more research is needed to confirm CBT’s specific health benefits. Overall, CBT represents one of many exciting new cannabinoid discoveries, and its role in the future of cannabinoid research is promising.
